齐多夫定与2',3'-双脱氧胞苷在体外对人免疫缺陷病毒1型（包括对齐多夫定耐药的毒株）复制的协同抑制作用。
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
作者信息
Eron J J, Johnson V A, Merrill D P, Chou T C, Hirsch M S
机构信息
Infectious Disease Unit, Massachusetts General Hospital, Boston.
出版信息
Antimicrob Agents Chemother. 1992 Jul;36(7):1559-62. doi: 10.1128/AAC.36.7.1559.
Abstract
The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by the median-effect principle and isobologram techniques. Cytotoxicity of the agents was not observed. Clinical trials are ongoing to define the combination's role in HIV-1 therapy.
摘要
齐多夫定（AZT）与2'，3'-双脱氧胞苷联合用药可协同抑制1型人类免疫缺陷病毒（HIV-1）在体外的复制，该病毒包括AZT敏感和耐药的临床分离株以及HIV-1IIIB。协同作用通过中位效应原理和等效线图技术确定。未观察到这些药物的细胞毒性。目前正在进行临床试验以确定该联合用药在HIV-1治疗中的作用。
相似文献
1
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
Antimicrob Agents Chemother. 1992 Jul;36(7):1559-62. doi: 10.1128/AAC.36.7.1559.
2
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Antimicrob Agents Chemother. 1994 Feb;38(2):288-93. doi: 10.1128/AAC.38.2.288.
3
Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
J Infect Dis. 1992 Nov;166(5):1143-6. doi: 10.1093/infdis/166.5.1143.
4
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Antimicrob Agents Chemother. 1996 May;40(5):1285-8. doi: 10.1128/AAC.40.5.1285.
5
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
J Infect Dis. 1991 Oct;164(4):646-55. doi: 10.1093/infdis/164.4.646.
6
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
Antimicrob Agents Chemother. 1991 May;35(5):988-91. doi: 10.1128/AAC.35.5.988.
7
Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
J Infect Dis. 1996 Feb;173(2):355-64. doi: 10.1093/infdis/173.2.355.
8
Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
Antimicrob Agents Chemother. 1991 Oct;35(10):2003-11. doi: 10.1128/AAC.35.10.2003.
9
Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine.
J Infect Dis. 1989 May;159(5):837-44. doi: 10.1093/infdis/159.5.837.
10
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
J Virol. 1996 Sep;70(9):5922-9. doi: 10.1128/JVI.70.9.5922-5929.1996.
引用本文的文献
1
The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription.
Virol J. 2015 Jul 25;12:108. doi: 10.1186/s12985-015-0339-8.
2
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. doi: 10.1128/AAC.03591-14. Epub 2014 Aug 4.
3
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.
Virology. 2012 Jan 5;422(1):22-36. doi: 10.1016/j.virol.2011.09.019. Epub 2011 Oct 22.
4
Combinatorial approaches to the prevention and treatment of HIV-1 infection.
Antimicrob Agents Chemother. 2011 May;55(5):1831-42. doi: 10.1128/AAC.00976-10. Epub 2011 Feb 22.
5
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
Retrovirology. 2009 May 13;6:44. doi: 10.1186/1742-4690-6-44.
6
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Antimicrob Agents Chemother. 1998 Jul;42(7):1799-804. doi: 10.1128/AAC.42.7.1799.
7
Zalcitabine population pharmacokinetics: application of radioimmunoassay.
Antimicrob Agents Chemother. 1998 Feb;42(2):409-13. doi: 10.1128/AAC.42.2.409.
8
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates.
Antimicrob Agents Chemother. 1997 Nov;41(11):2367-73. doi: 10.1128/AAC.41.11.2367.
9
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Antimicrob Agents Chemother. 1997 Oct;41(10):2159-64. doi: 10.1128/AAC.41.10.2159.
10
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Drugs. 1997 Jun;53(6):1054-80. doi: 10.2165/00003495-199753060-00009.
本文引用的文献
1
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
Adv Enzyme Regul. 1984;22:27-55. doi: 10.1016/0065-2571(84)90007-4.
2
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.
Science. 1984 May 4;224(4648):497-500. doi: 10.1126/science.6200935.
3
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.
Antimicrob Agents Chemother. 1987 Feb;31(2):168-72. doi: 10.1128/AAC.31.2.168.
4
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.
Antimicrob Agents Chemother. 1987 Oct;31(10):1613-7. doi: 10.1128/AAC.31.10.1613.
5
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
N Engl J Med. 1987 Jul 23;317(4):185-91. doi: 10.1056/NEJM198707233170401.
6
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911-5. doi: 10.1073/pnas.83.6.1911.
7
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Lancet. 1988 Jan 16;1(8577):76-81. doi: 10.1016/s0140-6736(88)90283-8.
8
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
J Exp Med. 1988 Sep 1;168(3):1111-25. doi: 10.1084/jem.168.3.1111.
9
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.
JAMA. 1989 Nov 3;262(17):2405-10.
10
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.
N Engl J Med. 1989 Sep 14;321(11):726-38. doi: 10.1056/NEJM198909143211106.
Zotero 插件